Neurodegenerative disease companies develop therapeutics, diagnostics and research technologies for conditions involving the progressive loss of neurons and nervous system function. Their work aims to improve disease detection, slow progression and address the underlying biology of neurodegeneration.
This category includes companies working on:
Browse 109 UK neurodegenerative disease companies below.
Probiotic contract manufacturer and Lab4 platform developer
Cultech is a Welsh contract developer and manufacturer of probiotic and nutritional supplement products, operating one of the world's most advanced probiotic manufacturing facilities at its Port Talbot site. The company owns the proprietary Lab4 probiotic consortium, backed by over 35 clinical trials and ten PhD…
Gene therapy company targeting inherited and degenerative diseases
MeiraGTx is a vertically integrated, clinical-stage genetic medicines company developing AAV-based gene therapies for inherited retinal diseases, neurodegenerative conditions, and salivary gland disorders. The company operates end-to-end capabilities spanning viral vector design, GMP manufacturing, and clinical…
Regenerative cell therapy for sensorineural hearing loss
Rinri Therapeutics is a clinical-stage biotech developing allogeneic regenerative cell therapies for sensorineural hearing loss, a condition affecting over 400 million people worldwide for which no disease-modifying treatment currently exists. Its lead programme, Rincell-1, is an otic neural progenitor cell therapy…
Small molecule drugs targeting astrocytes in neurodegenerative disease
AstronauTx is a clinical-stage UK biotech developing oral small molecule therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's approach targets astrocytes, brain support cells whose dysregulated inflammatory activity contributes to neurodegeneration, aiming to restore normal…
RNA-based therapeutics targeting neurodegenerative disease mechanisms
Harness Therapeutics is a Cambridge-based biotech developing oligonucleotide therapeutics that exploit post-transcriptional regulation to achieve controlled upregulation of disease-relevant proteins in the CNS. Its lead programme targets FAN1 nuclease in Huntington's disease to limit somatic DNA repeat expansion, with…
DUB inhibitor therapeutics targeting mitophagy and degenerative disease
Mission Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule inhibitors of deubiquitylating enzymes to treat diseases driven by mitochondrial dysfunction. By targeting a mitochondria-localised DUB, the company's drug candidates are designed to enhance mitophagy, the cellular…
Global biopharma focused on severe neurological and immunological diseases
UCB Pharma is the UK subsidiary of UCB S.A., a Belgian biopharmaceutical company focused on the discovery and development of treatments for severe neurological and immunological diseases. The UK operation is one of UCB's three global R&D hubs, with capabilities spanning antibody discovery, small molecule development,…
Quantum-informed computational design of covalent drug candidates
Axiom Therapeutics is a London biotechnology company using molecular physics and machine learning to design covalent small-molecule medicines. Its computational drug-discovery platform models interactions between reactive compounds and biological targets, helping design selective inhibitors for difficult-to-drug…
Small molecule therapeutics targeting astrocytes in Parkinson's disease
Cellestial Health is a pre-clinical stage biotechnology company and University of Cambridge spinout developing small molecule therapeutics for Parkinson's disease and other neurodegenerative conditions. The company's approach targets astrocytic networks, a class of brain cells whose dysregulation contributes to…
Not-for-profit research organisation targeting intrinsically disordered proteins
Bind Research is the UK's first Focused Research Organisation, established to make intrinsically disordered proteins druggable targets for new medicines. The organisation integrates NMR spectroscopy, biophysical characterisation, chemoproteomics, and AI to build comprehensive datasets of disordered protein-small…
Birthplace of molecular biology researching fundamental processes in human disease
The MRC Laboratory of Molecular Biology researches fundamental biological processes at the level of atoms, molecules, cells and organisms, applying this knowledge to major problems in human health and disease. The Laboratory pioneered techniques including DNA sequencing, protein structure determination and the…
Preclinical to late-phase imaging and eClinical trial services
Perceptive is a contract research organisation providing imaging and eClinical services to pharmaceutical and biotechnology companies across the full drug development lifecycle. Its three divisions cover preclinical and in vivo imaging, clinical trial imaging core lab and independent central review, and randomisation…
Programmable RNA delivery platform targeting non-hepatic tissues
Sixfold Bioscience is a biotechnology company developing a programmable RNA-based delivery platform that exploits the body's natural extracellular RNA transport pathways to direct therapeutic RNA molecules to specific non-hepatic tissues and cell types. The platform uses computationally designed chemical modifications…
AI-driven mass spectrometry biomarker services for diagnostics and drug development
Guilford Street Laboratories Ltd is a contract research organisation providing machine learning-powered mass spectrometry services for biomarker discovery, assay development, and precision medicine. The company specialises in high-sensitivity multi-omic analysis of protein, lipid, and metabolite biomarkers, supporting…
VNAR antibody shuttles for brain-targeted biologic therapies
Ossianix is a biopharmaceutical company developing single-domain VNAR antibody platforms for targeted delivery of therapeutics across the blood-brain barrier. Its TXP1 shuttle binds transferrin receptor 1 to transport antibody-based medicines into the central nervous system. The company engineers antibody fusions and…
AI-powered drug discovery and repurposing for rare diseases
Healx is a clinical-stage biotech applying AI to drug discovery and repurposing for rare diseases. Its platform analyses drug and disease data at scale to identify novel treatment relationships, enabling multiple discovery programmes to run in parallel. The lead programme targeting neurofibromatosis type 1 entered…
Specialty biopharma with UK neurotoxin manufacturing hub
Ipsen is a French specialty biopharmaceutical company with one of three global hubs based in the UK. Its Wrexham site serves as the company's global neuroscience centre of excellence, responsible for research, development and manufacture of neurotoxin products including botulinum toxin. The London site houses…
Neuroimaging contract research organisation for clinical trial biomarker analysis
IXICO is a London-based imaging contract research organisation providing end-to-end neuroimaging services to biopharmaceutical companies conducting clinical trials in neurological diseases. The company collects, manages, and analyses MRI, PET, and SPECT imaging data from global trial sites, generating AI-driven…
AI-powered retinal biomarker platform for early detection of eye and brain disease
Novai is a biotechnology company commercialising DARC (Detection of Apoptosing Retinal Cells), a retinal biomarker platform combining a fluorescent biologic with an AI image analysis algorithm to detect single-cell apoptosis in the retina in vivo. FDA and MHRA approved as an exploratory biomarker, DARC enables early…
Tau-targeting therapeutics and diagnostics for neurodegenerative disease
TauRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments and diagnostics for Alzheimer's disease and related neurodegenerative disorders. Its pipeline centres on tau aggregation inhibitors, which target the pathological accumulation of tau protein implicated in dementia. The company's…